男性不妊症市場：検査、治療タイプ、エンドユーザー別-2025～2030年の世界予測

男性不妊症市場は、2023年に37億7,000万米ドルと評価され、2024年には40億9,000万米ドルに達すると予測され、CAGR 8.94％で成長し、2030年には68億8,000万米ドルに達すると予測されています。

男性不妊症市場の範囲は、男性生殖器の問題の要因に対処するために設計された様々な診断と治療手順を包含します。男性不妊症は、主に精子生産量の低下、精子機能の異常、または精子送達を妨げる閉塞が原因で、妊娠可能な女性パートナーに妊娠を引き起こすことができないものと定義されます。男性不妊症に対処する必要性は、年齢、ライフスタイル要因、環境暴露に起因する不妊症の世界の有病率の増加から生じています。その用途は、精液分析やホルモン評価などの診断検査から、投薬、手術、体外受精（IVF）や顕微授精（ICSI）を含む生殖補助医療（ART）などの治療まで多岐にわたります。最終用途の範囲は医療プロバイダー、不妊治療クリニック、研究機関にまで及び、診断ツールや治療介入における進歩の恩恵を受けています。

市場洞察によると、不妊治療に対する認識と社会的受容の高まりにより、男性不妊症治療に対する需要が拡大しています。成長に影響を与える主要要因としては、診断プラットフォームにおける技術革新とARTの幅広い利用可能性が挙げられます。遺伝子プロファイリングに基づいて治療計画を最適化し、成功率を向上させる個別化医療アプローチには潜在的な治療機会が存在します。しかし、高額な治療費、限られた保険適用範囲、男性不妊症に関連する社会文化的汚名といった課題に直面しており、これが市場の成長を阻害する可能性があります。イノベーションは、非侵襲的診断技術の開発や特定の分子経路を対象とする新規医薬品の探索で発展する可能性があります。さらに、デジタルヘルスプラットフォームを統合することで、プロセスを合理化し、患者エンゲージメントを高めることができます。

男性不妊症市場は技術主導の領域へと進化しており、研究主導型の企業が最先端のソリューションを導入する大きな機会となります。男性不妊症の汚名を返上するための教育キャンペーンや、コスト障壁を軽減する技術に投資する企業は、かなりの市場シェアを獲得することができると考えられます。特に医療支払者や支援団体と戦略的パートナーシップを結ぶことで、こうした制限に対処することが、市場拡大の触媒となり、イノベーションを促進することができます。

市場力学：急速に進化する男性不妊症市場における重要な市場洞察の解明

男性不妊症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 男性不妊症に対する認識と教育の高まり
  • 生活習慣に関連した要因による男性不妊症の有病率の増加
  • 男性不妊症の診断・治療サービスへのアクセス向上による医療インフラの拡大
• 市場抑制要因
  • 男性不妊症治療に伴う高コスト
• 市場機会
  • オーダーメイド治療による個別化医療の動向の高まり
  • 遺伝子編集の技術的進歩
• 市場課題
  • 男性不妊症治療に対する保険適用の制限

ポーターのファイブフォース：男性不妊症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、男性不妊症市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：男性不妊症市場における外部からの影響の把握

外部マクロ環境要因は、男性不妊症市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：男性不妊症市場における競合情勢の把握

男性不妊症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：男性不妊症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、男性不妊症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：男性不妊症市場における成功への道筋を描く

男性不妊症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 男性不妊症に関する認識と教育の向上
    • ライフスタイル関連の要因による男性不妊症症例の有病率の増加
    • 医療インフラの拡大と男性不妊症診断・治療サービスへのアクセスの向上
  • 抑制要因
    • 男性不妊症治療に伴う高額な費用
  • 機会
    • カスタマイズ型治療計画による個別化医療の動向が拡大
    • 遺伝子編集における技術の進歩
  • 課題
    • 男性不妊症治療に対する保険適用は限定的
• 市場セグメンテーション分析
  • 検査：包括的かつ正確な評価により、コンピューター支援精液分析の適用が増加
  • エンドユーザー：専門性と専門知識により、不妊治療センターでの男性不妊検査の導入が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 男性不妊症市場：検査別

• イントロダクション
• コンピューター支援精液分析
• DNAセグメント化技術
• 顕微鏡検査
• 酸化ストレス分析
• 精子凝集
• 精子浸透アッセイ

第7章 男性不妊症市場：治療タイプ別

• イントロダクション
• 生殖補助技術と手術
• 薬剤治療

第8章 男性不妊症市場：エンドユーザー別

• イントロダクション
• 不妊治療センター
• 病院・クリニック
• 研究機関

第9章 南北アメリカの男性不妊症市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の男性不妊症市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの男性不妊症市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Birla Fertility & IVFが不妊治療のアクセス性と質の向上を目指してARMC IVFを買収
  • Maven Clinicが新たな男性不妊症サポートと拡大されたバーチャルケアで不妊治療プログラムを強化
  • ICMR Nagpurが男性不妊症の遺伝的原因を特定するための画期的なキットを開発
• 戦略分析と提言

企業一覧

• Aarti Medicals Pvt. Ltd.
• Adorefem
• Andrology Solutions
• Bayer AG
• CinnaGen Co.
• Cipla Limited
• Dallas IVF
• Ferring Global
• Gladfem by Zoic Group
• Glenmark Pharmaceuticals Limited
• HCA International Limited
• Intas Pharmaceuticals Ltd.
• Male Fertility & Sexual Medicine Specialists
• Maze Laboratories
• Merck KGaA
• Midwest Fertility Specialists
• NTMIC Sperm Lab
• Oasis Fertility
• SCSA Diagnostics, Inc.
• Shady Grove Fertility
• Sun Pharmaceutical Industries Limited
• Theramex
• Vitrolife Sweden AB
• Winfertility
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. MALE INFERTILITY MARKET RESEARCH PROCESS
• FIGURE 2. MALE INFERTILITY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MALE INFERTILITY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MALE INFERTILITY MARKET DYNAMICS
• TABLE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY COMPUTER-ASSISTED SEMEN ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY DNA FRAGMENTATION TECHNIQUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPIC EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY OXIDATIVE STRESS ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MALE INFERTILITY MARKET SIZE, BY SPERM AGGLUTINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MALE INFERTILITY MARKET SIZE, BY SPERM PENETRATION ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGIES & SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 32. CANADA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES MALE INFERTILITY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 49. CHINA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 52. INDIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 104. ITALY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 116. POLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 119. QATAR MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2023

The Male Infertility Market was valued at USD 3.77 billion in 2023, expected to reach USD 4.09 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 6.88 billion by 2030.

The scope of the male infertility market encompasses various diagnostic and treatment procedures designed to address factors contributing to male reproductive issues. Male infertility is defined as the inability to cause pregnancy in a fertile female partner, primarily due to low sperm production, abnormal sperm function, or blockages that prevent sperm delivery. The necessity of addressing male infertility arises from the increasing prevalence of infertility cases globally, driven by age, lifestyle factors, and environmental exposures. Its applications range from diagnostic testing, such as semen analysis and hormonal evaluations, to treatments like medication, surgery, and assisted reproductive technologies (ART) including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). The end-use scope extends to healthcare providers, fertility clinics, and research institutions, which benefit from advancements in diagnostic tools and therapeutic interventions.

Market insights reveal a growing demand for male infertility treatments attributed to increased awareness and societal acceptance of fertility health. Key factors influencing growth include technological innovations in diagnostic platforms and the broader availability of ARTs. There exists potential opportunities in personalized medicine approaches, which can optimize treatment plans based on genetic profiling, improving success rates. However, the market faces challenges such as high treatment costs, limited insurance coverage, and the socio-cultural stigmatization associated with male infertility, which may impede growth. Innovation can thrive in the development of non-invasive diagnostic techniques and the exploration of novel pharmaceuticals targeting specific molecular pathways. Furthermore, integrating digital health platforms could streamline processes and enhance patient engagement.

The male infertility market is evolving into a technologically-driven domain that provides a significant opportunity for research-driven companies to introduce cutting-edge solutions. Companies that invest in educational campaigns to destigmatize male infertility and in technologies that reduce cost barriers will be well-positioned to capture a substantial market share. Addressing these limitations, particularly by forming strategic partnerships with healthcare payers and advocacy groups, can catalyze market expansion and foster innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Male Infertility Market

The Male Infertility Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing awareness and education about male infertility
  • Increased prevalence of male infertility cases due to lifestyle-related factors
  • Expanding healthcare infrastructure with enhanced accessibility to male infertility diagnostic and treatment services
• Market Restraints
  • High costs associated with male infertility treatments
• Market Opportunities
  • Growing trend of personalized medicine with tailored treatment plans
  • Technological advancements in gene-editing
• Market Challenges
  • Limited insurance coverage for male infertility treatments

Porter's Five Forces: A Strategic Tool for Navigating the Male Infertility Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Male Infertility Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Male Infertility Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Male Infertility Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Male Infertility Market

A detailed market share analysis in the Male Infertility Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Male Infertility Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Male Infertility Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Male Infertility Market

A strategic analysis of the Male Infertility Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Male Infertility Market, highlighting leading vendors and their innovative profiles. These include Aarti Medicals Pvt. Ltd., Adorefem, Andrology Solutions, Bayer AG, CinnaGen Co., Cipla Limited, Dallas IVF, Ferring Global, Gladfem by Zoic Group, Glenmark Pharmaceuticals Limited, HCA International Limited, Intas Pharmaceuticals Ltd., Male Fertility & Sexual Medicine Specialists, Maze Laboratories, Merck KGaA, Midwest Fertility Specialists, NTMIC Sperm Lab, Oasis Fertility, SCSA Diagnostics, Inc., Shady Grove Fertility, Sun Pharmaceutical Industries Limited, Theramex, Vitrolife Sweden AB, Winfertility, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Male Infertility Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test, market is studied across Computer-Assisted Semen Analysis, DNA Fragmentation Technique, Microscopic Examination, Oxidative Stress Analysis, Sperm Agglutination, and Sperm Penetration Assay.
• Based on Treatment Type, market is studied across Assisted Reproductive Technologies & Surgery and Medication.
• Based on End User, market is studied across Fertility Centers, Hospitals & Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing awareness and education about male infertility
    • 5.1.1.2. Increased prevalence of male infertility cases due to lifestyle-related factors
    • 5.1.1.3. Expanding healthcare infrastructure with enhanced accessibility to male infertility diagnostic and treatment services
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with male infertility treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing trend of personalized medicine with tailored treatment plans
    • 5.1.3.2. Technological advancements in gene-editing
  • 5.1.4. Challenges
    • 5.1.4.1. Limited insurance coverage for male infertility treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Test: Rising application of computer-assisted semen analysis owing to comprehensive and accurate assessments
  • 5.2.2. End User: Increasing incorporation of male fertility tests in fertility centers due to specialization and expertise
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Male Infertility Market, by Test

• 6.1. Introduction
• 6.2. Computer-Assisted Semen Analysis
• 6.3. DNA Fragmentation Technique
• 6.4. Microscopic Examination
• 6.5. Oxidative Stress Analysis
• 6.6. Sperm Agglutination
• 6.7. Sperm Penetration Assay

7. Male Infertility Market, by Treatment Type

• 7.1. Introduction
• 7.2. Assisted Reproductive Technologies & Surgery
• 7.3. Medication

8. Male Infertility Market, by End User

• 8.1. Introduction
• 8.2. Fertility Centers
• 8.3. Hospitals & Clinics
• 8.4. Research Institutes

9. Americas Male Infertility Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Male Infertility Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Male Infertility Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Birla Fertility & IVF Acquires ARMC IVF to Improve Accessibility and Quality of Infertility Treatment
  • 12.3.2. Maven Clinic Enhances Fertility Program with New Male Infertility Support and Expanded Virtual Care
  • 12.3.3. ICMR Nagpur Develops Breakthrough Kit to Identify Genetic Causes of Male Infertility
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aarti Medicals Pvt. Ltd.
• 2. Adorefem
• 3. Andrology Solutions
• 4. Bayer AG
• 5. CinnaGen Co.
• 6. Cipla Limited
• 7. Dallas IVF
• 8. Ferring Global
• 9. Gladfem by Zoic Group
• 10. Glenmark Pharmaceuticals Limited
• 11. HCA International Limited
• 12. Intas Pharmaceuticals Ltd.
• 13. Male Fertility & Sexual Medicine Specialists
• 14. Maze Laboratories
• 15. Merck KGaA
• 16. Midwest Fertility Specialists
• 17. NTMIC Sperm Lab
• 18. Oasis Fertility
• 19. SCSA Diagnostics, Inc.
• 20. Shady Grove Fertility
• 21. Sun Pharmaceutical Industries Limited
• 22. Theramex
• 23. Vitrolife Sweden AB
• 24. Winfertility
• 25. Zydus Lifesciences Limited